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Components of Metabolic Syndrome and 5-Year Chance in Insulin Clearance The Resistance Atherosclerosis Study (IRAS)
Abstract

Aims
Cross-sectional evidence indicates that abdominal adiposity, hypertension, dyslipidaemia and glycaemia
are associated with reduced metabolic clearance rate of insulin (MCRI). Little is known about the
progression of MCRI and whether components of metabolic syndrome are associated with the change in
MCRI. In this study, we examined the association between components of metabolic syndrome and the
5-year change of MCRI.

Methods
At baseline and 5-year follow-up, we measured fasting plasma triglycerides (TG), high-density lipoprotein
(HDL) cholesterol, blood pressure (BP), waist circumference (WC) and fasting blood glucose (FBG) in 784
non-diabetic participants in the Insulin Resistance Atherosclerosis Study. MCRI, insulin sensitivity (SI) and
acute insulin response (AIR) were determined from frequently sampled intravenous glucose tolerance
tests.

Results
We observed a 29% decline of MCRI at follow-up. TG, systolic BP and WC at baseline were inversely
associated with a decline of MCRI regression models adjusted for age, sex, ethnicity, smoking, alcohol
consumption, energy expenditure, family history of diabetes, BMI, SI and AIR [β = −0.057 (95% confidence
interval, CI: −0.11, −0.0084) for TG, β = −0.0019 (95% CI: −0.0035, −0.00023) for systolic BP and β =
−0.0084 (95% CI: −0.013, −0.0039) for WC; all p < 0.05]. Higher HDL cholesterol at baseline was
associated with an increase in MCRI [multivariable-adjusted β = 0.0029 (95% CI: 0.0010, 0.0048), p =
0.002]. FBG at baseline was not associated with MCRI at follow-up [multivariable-adjusted β = 0.0014
(95% CI: −0.0026, 0.0029)].

Conclusions
MCRI declined progressively over 5 years in a non-diabetic cohort. Components of metabolic syndrome at
baseline were associated with a significant change in MCRI.
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Abstract
Aims—Cross-sectional evidence indicates that abdominal adiposity, hypertension, dyslipidemia
and glycemia are associated with reduced metabolic clearance of insulin (MCRI). Little is known
about the progression of MCRI and whether components of metabolic syndrome are associated
with the change in MCRI. In this study, we examined the association between components of
metabolic syndrome and the 5-year change of MCRI.
Methods and Materials—At baseline and 5-year follow-up, we measured fasting plasma
triglycerides (TG), high density lipoprotein (HDL)-cholesterol, blood pressure (BP), waist
circumference (WC) and fasting blood glucose (FBG) in 784 non-diabetic participants in the
Insulin Resistance Atherosclerosis Study. MCRI, insulin sensitivity (SI) and acute insulin response
(AIR) were determined from frequently sampled intravenous glucose tolerance tests.
Results—We observed a 29% decline of MCRI at follow-up. TG, systolic BP and WC at
baseline were inversely associated with a decline of MCRI regression models adjusted for age,
sex, ethnicity, smoking, alcohol consumption, energy expenditure, family history of diabetes,

Corresponding author: Anthony J. Hanley, PhD Department of Nutritional Sciences FitzGerald Building, University of Toronto 150
College St, Room 341 Toronto, ON, M5S 3E2 anthony.hanley@utoronto.ca phone: 416-978-3616 fax: 416-978-5882.
Declaration of interests The authors have no conflict of interests to disclose.

Lee et al.

Page 2

BMI, SI and AIR (β= −0.057 [95% CI −0.11, −0.0084] for TG, β= −0.0019 [95% CI −0.0035,
−0.00023] for systolic BP, β= −0.0084 [95% CI −0.013, −0.0039] for WC; all p<0.05). Higher
HDL-cholesterol at baseline was associated with an increase in MCRI (multivariable-adjusted β=
0.0029 [95% CI 0.0010, 0.0048], p=0.002). FBG at baseline was not associated with MCRI at
follow-up (multivariable-adjusted β= 0.0014 [95% CI −0.0026, 0.0029]).
Conclusions—MCRI declined progressively over 5 years in a non-diabetic cohort. Components
of metabolic syndrome at baseline were associated with a significant change in MCRI.

Introduction
Type 2 diabetes is reaching epidemic proportions, thus there is an urgent need for a better
understanding of pathophysiological mechanisms underlying diabetes to prevent its onset
and slow its progression. It is well-established that insulin resistance and pancreatic beta-cell
dysfunction are critical metabolic disorders underlying the development of type 2 diabetes
[1], although less is known regarding insulin clearance. Insulin clearance is a dynamic
physiological process in insulin metabolism in which a large proportion of insulin is
removed from the circulation after secretion, mostly by the liver and the reminder by the
kidney and other tissues [2–3]. It is reduced during the emergence of insulin resistance as a
compensatory mechanism to preserve beta-cell function in pre-diabetes states [4–6]. Despite
its importance in the metabolism of insulin and its potential role in the etiology of diabetes,
few studies had examined the dynamic change of insulin clearance over time.
Diabetes is closely related to a constellation of metabolic factors, including abdominal
adiposity, hypertension, hyperglycemia and dyslipidemia. The clustering of these risk
factors, a phenomenon referred to as metabolic syndrome, raises the risk of cardiovascular
disease [7–8]. Clinically, metabolic syndrome is manifested as high blood pressure (BP),
large waist circumference (WC), low plasma high-density-lipoprotein (HDL) cholesterol,
high plasma triglycerides (TG) and high fasting blood glucose (FBG) [9]. Previous crosssectional studies showed that insulin clearance is decreased in individuals with abdominal
adiposity [10–11] or hypertension [12–13]. However, to our knowledge, no studies have
investigated the prospective association between components of metabolic syndrome and
change in metabolic clearance rate of insulin (MCRI). In this study, we estimated insulin
clearance using MCRI which is derived from the frequently sampled intravenous glucose
tolerance tests (FSIGTT) [14], and aimed to describe the longitudinal progression of MCRI,
as well as to explore the association between components of metabolic syndrome (systolic
BP, WC, plasma HDL-cholesterol, plasma TG, FBG) at baseline and the difference in MCRI
between baseline and 5-year follow-up examinations in the Insulin Resistance
Atherosclerosis Study (IRAS).

Methods and Materials
The IRAS is a multicenter epidemiologic study designed to explore the relationships
between insulin resistance, cardiovascular disease and its known risk factors among nonHispanic whites, Hispanics and African-Americans with varying states of glucose tolerance.
Details of the study population and methods have been described [15]. The institutional
review boards at each study site approved the study protocol and all participants provided
written informed consent. The IRAS recruited 1,625 participants from four clinical centers
located in San Antonio, TX, San Luis Valley, CO, Oakland, CA and Los Angeles, CA
between October 1992 and April 1994. Participants were followed for an average of 5.2
years (range 4.5–6.6 years). After excluding individuals with prevalent diabetes (n=537) and
those with missing data on MCRI from either baseline or follow-up examinations due to loss
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to follow-up (n=191) or technical issues (n=113), we included 784 non-diabetic participants
in the current report.
Examinations at both baseline and follow-up each constituted two visits, separated by one
week. Participants were asked before each visit to fast for 12 hours, to abstain from alcohol
and heavy exercise for 24 hours, and to abstain from smoking the morning of the
examination. During the first visit, a 75-gram oral glucose tolerance test was administered.
During the second visit, insulin sensitivity (SI), acute insulin response (AIR) and MCRI
were determined from a FSIGTT, with two modifications to the original protocol. First,
insulin, instead of tolbutamide, was injected to ensure adequate levels of plasma insulin to
calculate insulin sensitivity accurately across a broad range of glucose tolerance. Second, a
reduced sampling protocol, using 12 instead of 30 samples, was used because of the large
number of participants. Insulin resistance, expressed as SI, was calculated using minimal
model analysis. Insulin secretion was measured by AIR, defined as the average increase in
plasma insulin at time points 2 and 4 minutes after infusing glucose [16]. MCRI was
calculated as the ratio of the insulin dose over the incremental area under the curve of
insulin from 20 minutes to infinity [14] using the following equation:

where Dose represents the amount of insulin injected at 20 min, Ins(t) the plasma insulin
concentration in standard units at each FSIGTT sampling point and Ins(0) the fasting plasma
insulin concentration determined before injecting glucose in the FSIGTT.
Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. Body mass
index (BMI) was calculated as weight in kg divided by height in m2. WC was measured to
the nearest 0.5 cm using a steel tape. All anthropometric measurements were taken in
duplicate following standardized procedures and the averages of these measurements were
used in the analyses. Resting systolic and diastolic BP was recorded using a standard
mercury sphygmomanometer after a 5-minute rest. The average of the second and the third
readings were used in the analyses. Information on demographics (age, sex, ethnicity),
lifestyle factors (smoking, alcohol consumption, energy expenditure) and family history of
diabetes were collected in validated questionnaires by self-report [15].
Participants provided a fasting blood draw at each examination. Plasma glucose was
measured using the glucose oxidase technique on an auto-analyzer. Plasma lipids and
lipoproteins, including TG and HDL-cholesterol were determined at the central IRAS
laboratory using methods from the Lipid Research Clinics [17]. We defined metabolic
syndrome using the IDF/AHA harmonized criteria [18].
Statistical analysis
We summarized the characteristics of participants at baseline and at 5-year follow-up using
median and interquartile range for continuous variables and percentages for categorical
variables. We tested the difference in MCRI between baseline to follow-up examinations
using McNemar tests for categorical variables, paired t-tests for normally distributed
continuous variables and Wilcoxon signed rank tests for non-normally distributed
continuous variables. We stratified these descriptive statistics by sex, ethnicity, family
history of diabetes and glycemic status at baseline, and tested the difference in the
percentage of change in these subgroups using t-tests. We described the relationship
between each component of metabolic syndrome and MCRI at baseline using Spearman’s
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rank correlation coefficient. We plotted the means and standard errors of MCRI at baseline
by the number of the components of metabolic syndrome at baseline.
Since the distribution of TG, MCRI and AIR were skewed, we natural log-transformed them
to achieve normality for subsequent analyses. Because of the presence of 0 values for SI, we
added a constant of 1 to all values of SI before the log-transformation. We used unadjusted
and multivariable-adjusted linear regression to explore the association between components
of metabolic syndrome at baseline and change in MCRI over time. We modeled TG, HDLcholesterol, FBG, systolic BP and WC at baseline as continuous exposures. In regression
models, we modeled MCRI at follow-up as the continuous outcome, and then adjusted for
MCRI at baseline to obtain the estimates for the difference of MCRI between two
examinations [19]. We presented the regression coefficients (β) with their 95% confidence
intervals (CI).
We included covariates in multivariable-adjusted models if they were associated with both
the exposure and the outcome, or if they were of a priori clinical relevance. Potential
confounders included age, sex, ethnicity, smoking, alcohol consumption, energy
expenditure, family history of diabetes, BMI, SI, AIR and FBG (except in the model where
FBG was the exposure). We examined the interaction of each of the components of
metabolic syndrome at baseline with age, sex, ethnicity, BMI, glycemic status on the change
in MCRI over time. In sensitivity analysis, we performed a backward stepwise regression
analysis which included all components of metabolic syndrome in the model to determine
which of these components was independently associated with the change in MCRI over
time when modeled together. Statistical analyses were performed using STATA 12.0
(StataCorp, College Station, TX, USA).

Results
Of the 784 non-diabetic participants with data on MCRI at baseline and follow-up
examinations, 315 (40%) were non-Hispanic whites, 199 (25%) were African-Americans
and 270 (35%) were Hispanics. Among these participants, 45% were women and 60%
reported to have family history of diabetes. At baseline, the median age of the study
population was 54 years (range 40–69 years) and 33% had impaired glucose tolerance.
Using the IDF/AHA harmonized criteria, 86% of the study population has at least one
component of metabolic syndrome. The prevalence of metabolic syndrome was 29.6% for
one component, 26.3% for two components, 18.0% for three components, 10.1% for four
components and 1.7% for five components. The IRAS participants had lower MCRI at
baseline as the number of components of metabolic syndrome increased (p<0.0001, Figure
1). Systolic BP, WC, FBG and TG were inversely correlated with MCRI, whereas HDL was
positively correlated (all p<0.001) (Table 1).
Participants had a significant decline in MCRI, SI, systolic BP and smoking, but an increase
in BMI, WC, HDL-cholesterol, FBG and AIR at the 5-year follow-up examination (all
p<0.0001). Plasma TG was not significantly different between baseline and follow-up
examinations (Table 2). The magnitude of the decline in MCRI was similar between
categories of sex, ethnicity and family history of diabetes. Despite having higher values of
MCRI at baseline and at follow-up, participants with normal glucose tolerance had greater
decline of MCRI over time than those with impaired glucose tolerance at baseline (Table 3).
In unadjusted linear regression models, higher systolic BP at baseline was associated with a
decline of MCRI over time. The significant association remained after adjusting for age, sex,
ethnicity, smoking, alcohol consumption, energy expenditure, family history of diabetes,
BMI, FBG, SI and AIR. Plasma TG at baseline was inversely associated with MCRI at
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follow-up in unadjusted regression models. Adjusting for demographic and lifestyle factors,
as well as known risk factors of diabetes did not change the association materially.
Similarly, larger WC at baseline was associated with a lower MCRI at follow-up in both
unadjusted and multivariable-adjusted regression models. Higher HDL-cholesterol at
baseline was associated with an increase in MCRI over time in unadjusted regression models
and after multivariable adjustment. However, there was no association between FBG at
baseline and the change in MCRI in both unadjusted and multivariable-adjusted regression
models (Table 4). We did not find significant interactions of any of the components of
metabolic syndrome with age, sex, ethnicity, BMI, glycemic status at baseline on the change
in MCRI over time. In sensitivity analysis, when including all components of metabolic
syndrome in a backward stepwise regression model, we observed that WC, HDL-cholesterol
and systolic blood pressure, but not triglyceride and fasting blood glucose, were
independently associated with the change in MCRI over time.

Discussion
In this multi-ethnic cohort of individuals with high prevalence of metabolic syndrome, we
observed a 29% decline of MCRI in a 5-year follow-up period. Overall, the IRAS
participants deteriorated metabolically between baseline and follow-up examinations, with
slight improvements in systolic blood pressure and HDL-cholesterol. This progressive
nature of metabolic abnormalities in our study population may explain the large decline of
MCRI over time. Compared to individuals with normal glycemia, those with impaired
glucose tolerance had lower MCRI at baseline, but a slower decline in MCRI over time.
Higher plasma TG and larger WC at baseline were associated with a decline in MCRI. In
contrast, higher HDL-cholesterol at baseline was associated with an increase in MCRI.
Higher systolic BP at baseline was associated with a lower MCRI at follow-up. When
considering all components of metabolic syndrome as a whole, WC, systolic BP and HDLcholesterol were independently associated with the change in MCRI over time. Our study
reports several novel findings on insulin clearance. First, we document for the first time the
progressive decline in MCRI. Second, we describe the longitudinal association between
components of metabolic syndrome at baseline and change in MCRI; these findings extend
the existing literature on this topic, which had consisted of mostly cross-sectional studies.
In our study population, individuals with impaired glucose tolerance had lower MCRI, lower
SI and lower AIR than those with normal glycemia. These metabolic traits correspond to
insulin resistance and beta-cell dysfunction which predispose to type 2 diabetes [20].
However, these individuals also had a relatively slower rate of decline in MCRI. Although
previous animal models have suggested that the decline in MCRI may represent an adaptive
mechanism during the evolution of insulin resistance to preserve β-cell function in prediabetes states [4], further experimental studies have yet to determine whether the rate of
decline slows later in the pathogenesis of diabetes.
Individuals with essential hypertension have a high prevalence of hyperinsulinemia [21].
Previous cross-sectional studies demonstrated an association between essential hypertension
and impaired insulin clearance in various populations [12–13]. Elevated fasting insulin is
associated with reduced hepatic insulin clearance to a greater extent than with increased
pancreatic insulin secretion in hypertensive individuals [22]. However, the temporality of
this association is unclear. In our study, we observed that higher systolic BP at baseline was
significantly associated with a decline of MCRI over time. Hypertension may decrease
MCRI through mechanisms involving capillary permeability. There is evidence suggesting
that elevated BP is associated with abnormal capillary permeability [23], and impaired
capillary transport from decreased blood flow or permeability could decrease the efflux of
insulin from the intravascular space, hence decreasing insulin clearance and resulting in an
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increase in plasma insulin if this occurs in tissues that are targeted for insulin degradation
[13]. Several clinical studies supported that certain classes of anti-hypertensive medication,
such as calcium channel blockers or alpha-adrenergic blockers, may augment insulin
clearance [24–25]. Nonetheless, long-term randomized controlled trials are needed to
determine the clinical significance of therapeutic intervention in lowering blood pressure on
insulin clearance.
Larger WC at baseline was associated with a significant decline in MCRI over time.
Consistent with our findings, previous cross-sectional studies have demonstrated that insulin
clearance is decreased in individuals with abdominal adiposity [10–11]. These associations
are biologically plausible, as abdominal adiposity increases the release of free fatty acids
from adipose tissues, resulting in hyperinsulinemia and leading to a decline in insulin
clearance [26–27]. Given its significance in the decline of insulin clearance, decreasing
abdominal adiposity could be used as a therapeutic target. To support this notion, restricting
caloric intake of diabetic patients has been shown to result in weight loss, decrease insulin
resistance and increase insulin clearance [28].
Our study showed that higher plasma TG at baseline was associated with the decline of
MCRI over time. With respect to HDL-cholesterol, we observed a positive association with
the change in MCRI. In stepwise regression models, HDL-cholesterol, but not plasma TG,
independently associated with the change in MCRI which may be related to their strong
inverse correlations. Insulin resistance is associated with abnormal lipid metabolism,
including elevated plasma TG and decreased HDL-cholesterol [29]. In individuals with
impaired glucose tolerance, elevated plasma TG is significantly associated with increased
HDL-cholesterol catabolism [30]. Mechanistically, insulin resistance and/or
hyperinsulinemia could increase serum free fatty acids or divert dietary carbohydrates to
become substrates for de novo lipogenesis, resulting in an increase in hepatic synthesis of
TG [8, 31]. Insulin resistance could also decrease HDL-cholesterol by blunting the
stimulation of lipoprotein lipase activity, increasing triglyceride-enrichment of HDL and
increasing hepatic lipase activity [32–33]. Since elevated TG and decreased HDLcholesterol are associated with insulin resistance, and insulin resistance precedes the
reduction of insulin clearance [4], it is plausible that abnormal lipids are associated with
impaired insulin clearance, as we observed in the present study. Alternatively, dyslipidemia
in metabolic syndrome is closely related to non-alcoholic fatty liver disease [34]. Insulin
clearance was reduced in individuals with increased liver fat [35], whereas therapeutic
intervention with rosiglitazone reduced liver fat and increased insulin clearance [36].
Higher FBG at baseline was not associated with MCRI at follow-up. Our participants were
diabetes-free at baseline and their median FBG was in the normal range. This may explain
the lack of association between FBG at baseline and MCRI at follow-up, as elevated FBG
may correspond to the decline of insulin sensitivity and insulin clearance, thus emerge in the
later stages of the etiology of type 2 diabetes.
The strengths of our study include the well-characterized multi-ethnic cohort, detailed and
direct measurements of insulin clearance, insulin sensitivity and β-cell function, and the
prospective design which allows us to explore the temporal relationship of the exposure
variables with the change of MCRI over time. However, our findings may apply only to
individuals with similar demographic characteristics and may not be generalized to other
ethnic populations.
In conclusion, we demonstrated a progressive decline of MCRI in the non-diabetic
participants of the IRAS. Components of metabolic syndrome at baseline, including
dyslipidemia, hypertension and abdominal adiposity, were associated with a decline of
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MCRI over time. These findings provide a basis for long-term randomized controlled trials
to confirm that reducing weight, improving lipids and blood pressure through
pharmaceutical or lifestyle intervention could improve insulin clearance and hence slow the
onset of diabetes in high risk populations.
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Figure 1.

Means (standard errors) of MCRI, stratified by the number of components of metabolic
syndrome at baseline
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Table 1

Spearman correlation analysis between components of metabolic syndrome and MCRI at baseline
MCRI

p-value

Systolic BP

−0.138

0.0001

Waist circumference

−0.528

<0.0001

HDL-cholesterol

0.305

<0.0001

Plasma triglycerides

−0.234

<0.0001

Fasting blood glucose

−0.214

<0.0001
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Table 2

Characteristics of 784 non-diabetic participants at baseline and at 5-year follow-up in the IRAS
Baseline

Follow-up

Change

%
change

p-value

MCRI (l/min)

5.28 (3.92, 7.10)

3.67 (2.87, 4.80)

−1.47 (−2.91, −0.34)

−29.4

<0.0001

BMI (kg/m2)

27.3 (24.9, 30.5)

28.1 (25.3, 31.5)

0.72 (−0.36, 1.74)

2.67

<0.0001

WC (cm)

90.0 (81.3, 97.8)

92.3 (83.9, 99.9)

2.7 (−0.5, 5.9)

3.10

<0.0001

Systolic BP (mmHg)

121 (110, 133)

118 (107, 130)

−2 (−8, 3)

−1.85

<0.0001

TG (mg/dl)

111 (79, 159)

112 (79, 162)

−1 (−26, 29)

−1.12

0.98

HDL (mg/dl)

44 (36, 55)

46 (38, 58)

2 (−3, 7)

4.50

<0.0001

FBG (mg/dl)

97 (91, 105)

98 (91, 109)

2.5 (−3.5, 8.8)

2.35

<0.0001

AIR (μU/ml)
SI

(×10−4

min−1

[μU/l]−1)

51 (29, 86)

65 (35, 105)

10 (−8, 36)

22.7

<0.0001

1.64 (0.94, 2.94)

1.02 (0.52, 1.73)

−0.6 (−1.43, 0)

−43.6

<0.0001

Current smoker (%)

126 (14.0)

91 (10.1)

−35 (−3.9)

−27.9

<0.0001

Energy expenditure
(kcal/kg/day)

38.5 (35.6, 43.3)

37.1 (34.8, 41.8)

−0.68 (−3.96, 2.62)

−1.78

0.0006

Data presented are medians (interquartile range) or n (%)
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Table 3

Values of MCRI at baseline and at 5-year follow-up of 784 non-diabetic participants in the IRAS, stratified by
sex, ethnicity, family history of diabetes and glycemic status
MCRI (l/min)

Baseline

Follow-up

Change

%change

p-value

Men

5.16 (3.92, 7.11)

3.52 (2.79, 4.60)

−1.52 (−3.17, −0.43)

−31.4

<0.0001

Women

5.32 (3.92, 7.06)

3.84 (2.95, 5.00)

−1.37 (−2.70, −0.31)

−27.7

<0.0001

By sex

*p=0.1 between groups
By ethnicity
Non-Hispanic
whites

5.73 (4.37, 7.61)

4.05 (3.10, 5.32)

−1.55 (−3.21, −0.44)

−28.9

<0.0001

African-Americans

5.20 (3.97, 6.51)

3.39 (2.60, 4.26)

−1.61 (−2.98, −0.83)

−34.5

<0.0001

Hispanics

4.81 (3.62, 6.56)

3.63 (2.82, 4.66)

−1.11 (−2.49, −0.014)

−24.1

<0.0001

*p=0.07 between groups
By family history of diabetes
Yes

4.84 (3.70, 6.46)

3.50 (2.61, 4.51)

−1.26 (−2.63, −0.33)

−27.3

<0.0001

No

5.55 (4.05, 7.37)

3.81 (3.02, 4.97)

−1.55 (−3.02, −0.36)

−30.1

<0.0001

*p=0.4 between groups
By glycemic status at baseline
NGT

5.54 (4.24, 7.41)

3.81 (3.03, 4.96)

−1.58 (−3.22, −0.44)

−31.3

<0.0001

IGT

4.71 (3.47, 6.10)

3.48 (2.61, 4.43)

−1.15 (−2.38, −0.079)

−26.8

<0.0001

*p=0.02 between groups
Data presented are medians (interquartile range) or n (%)

*

the p-value refers to the % change between groups
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Table 4

Estimated regression coefficients (95% confidence intervals) on the association between components of
metabolic syndrome at baseline and change in MCRI in non-diabetic participants of the IRAS
Outcome: follow-up ln(MCRI) (l/min)

Beta-coefficients (95% CI)

p-value

Unadjusted*

−0.0029 (−0.0044, −0.0013)

<0.001

adjusted for age, sex, ethnicity

−0.0028 (−0.0044, −0.0013)

<0.001

+ smoking, alcohol consumption, energy
expenditure, family history of diabetes

−0.0029 (−0.0045, −0.0012)

<0.001

+ BMI, fasting blood glucose

−0.0020 (−0.0036, −0.0038)

0.016

+ ln(SI), ln(AIR)

−0.0019 (−0.0035, −0.00023)

0.025

Unadjusted*

−0.011 (−0.013, −0.0087)

<0.001

adjusted for age, sex, ethnicity

−0.012 (−0.014, −0.0092)

<0.001

+ smoking, alcohol consumption, energy
expenditure, family history of diabetes

−0.011 (−0.014, −0.0089)

<0.001

+ BMI, fasting blood glucose

−0.0099 (−0.014, −0.0055)

<0.001

+ ln(SI), ln(AIR)

−0.0084 (−0.013, −0.0039)

<0.001

Unadjusted*

−0.057 (−0.11, −0.0098)

0.018

adjusted for age, sex, ethnicity

−0.088 (−0.14, −0.038)

0.001

+ smoking, alcohol consumption, energy
expenditure, family history of diabetes

−0.087 (−0.14, −0.037)

0.001

+ BMI, fasting blood glucose

−0.070 (−0.12, −0.022)

0.005

+ ln(SI), ln(AIR)

−0.057 (−0.11, −0.0084)

0.022

Unadjusted*

0.0038 (0.0021, 0.0056)

<0.001

adjusted for age, sex, ethnicity

0.0046 (0.0027, 0.0065)

<0.001

+ smoking, alcohol consumption, energy
expenditure, family history of diabetes

0.0045 (0.0025, 0.0064)

<0.001

+ BMI, fasting blood glucose

0.0036 (0.0017, 0.0055)

<0.001

+ ln(SI), ln(AIR)

0.0029 (0.0010, 0.0048)

0.002

Unadjusted*

−0.0019 (−0.0043, 0.00052)

0.125

adjusted for age, sex, ethnicity

−0.00089 (−0.0033, 0.0016)

0.476

+ smoking, alcohol consumption, energy
expenditure, family history of diabetes

−0.00082 (−0.0033, 0.0017)

0.516

+ BMI

0.0016 (−0.00086, 0.0040)

0.205

+ ln(SI), ln(AIR)

0.0014 (−0.0026, 0.0029)

0.921

Systolic blood pressure (mmHg)

Waist circumference (cm)

Ln(plasma triglyceride) (mg/dl)

HDL-cholesterol (mg/dl)

Fasting blood glucose (mg/dl)

*

adjusted for baseline ln(MCRI) in all models
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